New Zealand

Home / Species & Products / Horses / Fluvac Innovator® 4

Fluvac Innovator® 4

Only for use in horses intended for export

Each single dose (1mL) syringe contains vaccine consisting of a combination of equine encephalomyelitis Eastern and Western viruses, equine influenza type A2 (Kentucky 97) vaccine and tetanus toxoid.

Expand All
  • Approved uses/Indications

    For vaccination of healthy horses as an aid in the prevention of equine encephalomyelitis due to Eastern and Western viruses, equine influenza due to types A1 and A2 viruses, and tetanus.

  • Key Features

    An aid to stimulate immunity to both Eastern and Western equine encephalomyelitis, equine influenza type A2 and tetanus.

  • Dosage & Administration

    Inject 1 mL dose intramuscularly using aseptic technique. Administer a second 1 mL dose 3 to 4 weeks after the first dose. A 1 mL booster should be given annually, when exposure is likely, or at any time epidemic conditions exist. To promote absorption, mild exercise is recommended for 1 week after injection.

  • Precautions
    • Contraindications: Horses incubating other infections or suffering from malnutrition, parasitism or immune suppression are poor subjects for immunisation and may not develop or maintain an adequate immune response.
    • Side Effects: When used according to directions, it is unusual for reactions to appear, other than the occasional temporary local swelling at the site of injection. In the case of systemic anaphylactic reaction (excessive sweating or mild colic) administer epinephrine.
    • Special Precautions: Protective tetanus antibody titres usually develop two weeks after the second injection of the initial vaccination series. In the event of injury during the course of the initial vaccination program, or if annual boosters have not been given, a prophylactic dose of at least 1500 units of tetanus antitoxin should be given. Avoid stress in the animals around the time of vaccination. Shake well before use to ensure uniform suspension of the vaccine.
    • Other Information: Store between 2°C to 7°C (refrigerate. Do not freeze). Protect from light. Syringes or vaccinator’s guns should not have been sterilised chemically.
    • Withholding Periods: Manufacturer recommends not to vaccinate within 21 days of slaughter.
    • Handling Precautions: Accidental self-injection may cause an inflammatory or allergic response and immediate medical advice should be sought. Allergic or anaphylactic (Type 1 hypersensitivity) reactions may be caused by adjuvants, inactivated viral components or other vaccine components. Accidental self-injection should be treated as a contaminated puncture wound. Take the product with you so the medical practitioner is informed the product is adjuvanted. Repeated exposure may cause allergic response. Avoid skin contact.
    • Records to be Kept: To be administered to horses destined for export only. As a condition of registration under the Agricultural Compounds and Veterinary Medicines Act 1997, MAF Biosecurity New Zealand requires the supplied vaccination record form to be completed in full by the administering veterinarian at the time of vaccination and returned with 5 days to the New Zealand Equine Health Association Inc. Keep a record of all animals vaccinated. When a vaccinated horse is not exported, the New Zealand Equine Health Association must be advised to allow accurate records to be maintained.
  • Mandatories

    Zoetis Animal Health New Zealand Limited. Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand. Tel: 0800 650 277, Fax: 0800 628 629. FLUVAC Innovator is a registered trade mark of Zoetis Inc. or its subsidiaries. ACVM Registration No. A9282. RVM; Available only under Veterinary Authorisation.

  • Contact Information

    For technical enquiries regarding Fluvac Innovator 4 please phone: 0800 650 277 fax: 0800 628 629.